Hostname: page-component-78c5997874-lj6df Total loading time: 0 Render date: 2024-11-13T01:24:33.167Z Has data issue: false hasContentIssue false

77286 Intravital microscopy in the study of the tumor vasculature of patients with peritoneal carcinomatosis

Published online by Cambridge University Press:  30 March 2021

Emmanuel Gabriel
Affiliation:
Mayo Clinic Florida
Minhyung Kim
Affiliation:
Roswell Park
Daniel Fisher
Affiliation:
Roswell Park
Catherine Mangum
Affiliation:
Mayo Clinic Florida
Kristopher Attwood
Affiliation:
Roswell Park
Wenyan Ji
Affiliation:
Roswell Park
Debabrata Mukhopadhyay
Affiliation:
Mayo Clinic Florida
Sanjay Bagaria
Affiliation:
Mayo Clinic Florida
Matthew Robertson
Affiliation:
Mayo Clinic Florida
Tri Dinh
Affiliation:
Mayo Clinic Florida
Keith Knutson
Affiliation:
Mayo Clinic Florida
Joseph Skitzki
Affiliation:
Roswell Park
Michael Wallace
Affiliation:
Mayo Clinic Florida
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

ABSTRACT IMPACT: Investigation of tumor-associated blood vessels may serve as an imaging biomarker of response to systemic therapy and cancer outcomes. OBJECTIVES/GOALS: Aberrancies in the tumor microvasculature limit the systemic delivery of anticancer agents, which impedes tumor response. Using human intravital microscopy (HIVM), we hypothesized that HIVM would be feasible in patients with peritoneal carcinomatosis (PC) and generate clinical utility. METHODS/STUDY POPULATION: During cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for PC, HIVM was performed in both tumor and non-tumor areas. The primary outcome was HIVM feasibility to measure vessel characteristics. We secondarily evaluated associations between HIVM vessel characteristics and oncologic outcomes (RECIST response to neoadjuvant therapy and disease-specific survival). RESULTS/ANTICIPATED RESULTS: Thirty patients with PC were enrolled. Nineteen patients (63.3%) received neoadjuvant therapy. HIVM was feasible in all patients. Compared to non-tumor (control) areas, PC areas had a lower density of functional vessels, higher proportion of non-functional vessels, smaller lumenal diameters, and lower blood flow velocity. Qualitative differences in these vessel characteristics were observed among patients who had partial response, stable disease, or progressive disease after receiving neoadjuvant therapy. However, no statistically significant relationships were found between HIVM vessel characteristics and oncologic outcomes. DISCUSSION/SIGNIFICANCE OF FINDINGS: These novel findings comprise the first-in-human, real-time evidence of the microscopic differences between normal and tumor-associated vessels and form the basis for our larger, ongoing clinical trial appropriately powered to determine the clinical utility of HIVM (NCT03823144).

Type
Clinical Trial
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Association for Clinical and Translational Science 2021